Insights & Innovators

RWE Industry Insights

ICER’s Development and Use of RWE: 5 Areas for Concern

The pervasiveness of real-world data (RWD) and the need to understand outcomes in clinical practice have galvanized the ubiquity and utility of real-world evidence (RWE). Especially within the life sciences industry, RWE is increasingly leveraged by research and development, epidemiology, outcomes research, and commercial groups across an asset’s[…]

ICER

ICER Takes Aim at Rising Drug Prices: 7 Things to Know

Written by Charles Tao. As an organization that evaluates the comparative value of medical technologies, the Institute for Clinical and Economic Review (ICER) is no stranger to ruffling the feathers of the life sciences industry. Its track record of declaring that drugs are overpriced says it all (see our recent blog post for a fuller[…]

ICER

ICER Versus NICE: Who Cares About Value-Based Pricing Assessments?

This is my last post in an ICER versus NICE series that examines how ICER’s and NICE’s methodologies for implementing cost-effectiveness (CE) analyses differ. My last post explored how differences in the use of a fixed CE threshold and the application of a narrower CE threshold range may lead to different intervention recommendations. In this[…]

Instant Health Data

Put reliable, rapid analytics in the hands of more people across your organization

Learn more about Panalgo

Get the story behind our work and our team.